Drugs / Gentuximab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05223595 | Apr 2021 → Sep 2023 | non-small cell lung carcinoma | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03313219 | Oct 2017 → Dec 2019 | cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04053205 | Nov 2019 → Jun 2020 | gastroesophageal cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05919381 | May 2022 → Dec 2024 | gastric adenocarcinoma | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05223595 ↗ |
| Known as | Gentuximab Injection | “Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)” NCT03313219 ↗ |
| Modality | Monoclonal antibody | “human-mouse chimeric monoclonal antibody injection” NCT03313219 ↗ |
| Route | Intravenous | “intravenous infusion” NCT03313219 ↗ |